Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Benefits of Point-of-Care Glucose Testing and Insulin Supplementation at Bedtime in Insulin Treated Patients With Type 2 Diabetes
Brief Summary: Capillary point-of-care (POC) testing is advocated as a valuable aid in the management of diabetes and hyperglycemia in the hospital setting. POC testing aims at collecting information on BG levels at different time points during the day in order to assess glycemic control and to guide insulin adjustment/correction doses. Although POC testing provides insights into day-to-day excursions in BG levels, bedtime BG testing triggers the use of insulin supplements that may result in increased frequency of hypoglycemia and is expensive with an estimated annual cost in hospitals of several hundreds of millions of dollars in the U.S. Accordingly, this pilot study aims to assess the utility of POC and insulin supplementation (correction doses) at bedtime in improving glycemic control and in preventing hypoglycemia in non-ICU patients with type 2 diabetes mellitus (T2DM). A total of 250 non-ICU medical and surgical patients treated with basal bolus regimen will undergo POC testing before meals and bedtime (standard of care) and half of the patients will receive insulin correction doses at bedtime for BG \> 140 mg/dL following a sliding scale protocol, while the other half will be followed without insulin supplementation at bedtime except for extreme hyperglycemia (BG \> 350 mg/dl). Patients will be recruited at Emory University Hospital and Grady Memorial Hospital.


Options:
A: Arm Label: Basal Plus Regimen; Type: EXPERIMENTAL; Interventions: Drug: Basal Plus | Arm Label: Basal Bolus; Type: EXPERIMENTAL; Interventions: Drug: Basal Bolus | Arm Label: sliding scale regular insulin (SSRI); Type: ACTIVE_COMPARATOR; Interventions: Drug: sliding scale regular insulin (SSRI) | Intervention Type: DRUG; Name: sliding scale regular insulin (SSRI); Assigned to Arm(s): sliding scale regular insulin (SSRI) | Intervention Type: DRUG; Name: Basal Bolus; Assigned to Arm(s): Basal Bolus | Intervention Type: DRUG; Name: Basal Plus; Assigned to Arm(s): Basal Plus Regimen
B: Arm Label: Bedtime supplementation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bedtime insulin Aspart (Novolog) | Arm Label: no bedtime supplementation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bedtime insulin Aspart (Novolog); Assigned to Arm(s): Bedtime supplementation
C: Arm Label: sliding scale regular insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: sliding scale regular insulin | Arm Label: glargine insulin and glulisine insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: glargine basal insulin and glulisine prandial insulin | Intervention Type: DRUG; Name: sliding scale regular insulin; Assigned to Arm(s): sliding scale regular insulin | Intervention Type: DRUG; Name: glargine basal insulin and glulisine prandial insulin; Assigned to Arm(s): glargine insulin and glulisine insulin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin glargine, Drug: Insulin glulisine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Regular insulin | Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Regular insulin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Insulin glulisine; Assigned to Arm(s): 1

Answer: B